Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

For Pfizer, the consensus sales estimate for the current quarter of $17.5 billion indicates a year-over-year change of +22.8%. For the current and next fiscal years, $63.36 billion and $62.98 ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

Value investors rely on traditional forms of analysis on ... watch right now is Pfizer (PFE). PFE is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with ...

The stock's fall snapped a four-day winning streak.

Pfizer's EPS and revenue beat ... relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...